Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Agilent Technologies (A) Boasts Earnings & Price Momentum: Should You Buy?

Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.

Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe

BJ`s Wholesale Club Holdings Inc

Coinbase

Deere & Company

With August almost over and the back-to-school season upon us, the lion's share of the outstanding second-quarter earnings results have been posted, and analysts and investors on Wall Street are very satisfied with the results.

Goldman Sachs Boosts Price Targets on 4 Strong Buy-Rated Stocks

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company's PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer patients for treatment with KEYTRUDA using Combined Positive Score (CPS) ≥ 10.1 In Europe, KEYTRUDA is approved in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced unresectable or metastatic eso

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer

Agilent reported its fiscal Q3 results that beat expectations. The company is benefiting from strong demand across all end markets with its Diagnostics and Genomics Group leading growth.

Agilent Technologies: Momentum In Genomics Keeps It Interesting

Chipotle

Domino's Pizza

Hilton Worldwide Holdings

Lowe's

Bill Ackman (Trades, Portfolio), leader of Pershing Square Capital, has revealed his portfolio for the second quarter of the year. Top trades include reductions in Lowe's Companies Inc. ( LOW , Financial), Hilton Worldwide Holdings Inc. ( HLT , Financial), Restaurant Brands International Inc. ( QSR , Financial) and Agilent Technologies ( A , Financial) alongside an addition to his recently established position in Domino's Pizza Inc. ( DPZ , Financial).

Bill Ackman's Top 5 Trades of the 2nd Quarter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a rapid method for differentiating COVID-19-positive patients expected to show severe symptoms from those likely to experience only mild symptoms. The classification algorithm, published in the journal Analytical Chemistry, is based on infrared spectra of blood plas

Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer

Agilent's (A) fiscal third-quarter results benefit from strength across all geographical regions, business groups and end-market momentum.

Agilent (A) Q3 Earnings & Revenues Beat Estimates, Rise Y/Y

Agilent Technologies Inc (NYSE: A) reported third-quarter revenue of $1.59 billion, +26% and up 21% on a core basis, slightly beating the consensus of $1.54 billion. During the third quarter, revenues for the diagnostic and genomics group (DGG) rose 44% to $346 million.

Agilent Stock Trading At 52-Week High As Analysts Beef Up Target Price After Q3 Earnings

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q3 2021 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 11.11% and 3.67%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Q3 Earnings and Revenues Surpass Estimates

Shares of Agilent Technologies (NYSE:A) fell 0.6% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 41.03% year over year to $1.10, which beat the estimate of $0.99.

Recap: Agilent Technologies Q3 Earnings

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent reports strong fiscal third quarter financial results, raises full-year guidance.

Agilent Reports Third-Quarter Fiscal Year 2021 Financial Results

Agilent's (A) fiscal third-quarter results are likely to reflect strength across its segments and product portfolio.

Agilent (A) to Report Q3 Earnings: What's in the Cards?

Agilent Technologies (A) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Agilent Technologies (A) Ahead of Earnings?

Target

Ulta Beauty

Walmart

Five corporate bigwigs are slated to release their earnings results this month. These are: WMT, A, TGT, DE and ULTA.

5 Corporate Giants to Buy Ahead of Earnings Results This Month

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent earns 2021 Great Place to Work certification in the U.S.

Agilent Earns 2021 Great Place to Work Certification in the U.S.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that is has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China. Agilent is a leading provider of next-generation sequencing assays, and customers often develop custom panels for their routine applications. Therefore, delivery turnaround time is an essential aspect of how Agilent uniquely serves its customers, enabling them to validate and implement their as

Agilent Announces Target Enrichment Manufacturing Facility in China

Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Agilent Technologies (A) is a Great Choice

Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Agilent (A) Keep the Earnings Surprise Streak Alive?

Danaher

Robert Half Int.

3 Stocks With Price and Earnings Estimate Momentum

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Jason H. Yang, Ph.D., has received the 2021 Agilent Early Career Professor Award. Dr. Yang is an assistant professor of Microbiology, Biochemistry and Molecular Genetics in the Center for Emerging and Re-Emerging Pathogens at Rutgers New Jersey Medical School. This year's award focus was contributions to the development of breakthrough solutions to understand or manage immunological responses to infec

Agilent Early Career Professor Award Presented to Jason H. Yang

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions". The study, jointly published by Resolution Bioscience (now a part of Agilent) and Memorial Sloan Kettering Cancer Center (MSK), describes the use of plasma ctDNA NGS to detect novel anaplastic lymphoma kinase (ALK) fusions, and to serially moni

Clinical Utility of ALK Fusion Detection by Liquid Biopsy

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent issues 2020 corporate social responsibility report.

Agilent Technologies Celebrates More than 20 Years of Sustainable Progress

Agilent Technologies (A) expands the use of PD-L1 IHC 22C3 pharmDx assay for cancer treatment in the European Union.

News for Agilent Technologies Stock (A)